Latest news with #Evolysse
Cosmopolitan
04-08-2025
- Health
- Cosmopolitan
Evolysse Hyaluronic Acid Filler Review
It's not every day a new injectable hits the beauty market, so when I first heard about Evolysse, a new type of filler from Evolus (the makers of Jeuveau, a popular type of Botox), my ears immediately perked then my skin perked up, itching to give it a try. Yes, Evolysse is a filler. The dreaded f-word. But it promises to lead the way in rebranding the way social media has conditioned us to view filler in recent months (that it's bad, unnatural, and that it will leave your face looking puffy if overdone in just the slightest) thanks to a new technology that preserves the molecular structure of hyaluronic acid so it looks smooth and natural once injected. Intrigued? I was too—and was fortunate enough to get an early sneak peek of the newest FDA-approved injectable to see how it compares to the tried-and-true injectables currently on the market. I'm here to give my honest thoughts after trying it, and help set the record straight on where this injectable fits into your cosmetic treatment routine. Evolysse is a hyaluronic acid injectable. Hyaluronic acid is a molecule that's naturally occurring in our bodies that, when injected underneath the skin, can smooth out imperfections, add volume to areas of the face, and augment features such as the lips, chin, and jawline. You know how your hyaluronic acid serum makes your skin all plump, bouncy, and firm? When injected properly, hyaluronic fillers basically create that same effect but for the long term. Hyaluronic acid fillers have been around since the early aughts, but Evolysse is the first real technological innovation in the space in the last decade, says Julie K. Karen, MD, a board-certified dermatologist in New York, NY. "It's a new group of hyaluronic acid fillers that seeks to restore volume and smooth out the lower face in a very natural and smooth way because of the innovative technology by which they're developed,' explains Dr. Karen. Said innovative technology is called Cold-X Technology. It's what sets Evolysse apart from other hyaluronic acid-injectables on the market, and it helps protect the natural structure of the hyaluronic acid molecule. I'm going to get a little sciencey here, but the gist is that hyaluronic acid molecules are sensitive to warmer temperatures when manufactured for aesthetic use, though all current ones on the market are produced in this manner. When hyaluronic acid-injectables are made at very warm temperatures, it 'denatures the hyaluronic acid,' effectively causing it to break down into shorter fragments, which are then crosslinked to reconnect them for use. 'By processing the Evolysse line at cold, near-freezing temperatures, they preserve the natural structure of hyaluronic acid. This leads to a more natural-looking result, mimicking the actual existence of hyaluronic acid in the skin,' says Dr. Karen. This process also leads to more natural tissue integration and less swelling when the product is injected into the skin. Right now, Evolysse is FDA-approved to smooth dynamic smile lines and laugh lines in the lower face, though, depending on your provider's expertise, it can be injected off-label into other areas to volumize, smooth, or augment. Currently, the Evolysse line has two different types of filler in the U.S. market: Form and Smooth. 'Evolysse Smooth is softer and more pliable, making it suitable for more superficial lines like those around the mouth, like perioral lines, marionette lines, nasolabial folds,' says Connie Yang, MD, a board-certified dermatologist in New York, NY. 'I have injected Smooth in the lips and seen a beautiful, soft result,' says Dr. Yang. Evolysse Form, on the other hand, is firmer, more robust, and gel-like, making it 'suitable for deeper folds and areas needing more volume (like cheeks, jawline, etc.). It provides more structure and contour, which is great for areas that need more volume restoration and support,' she further explains. This all being said, Dr. Yang says the family of injectables 'are quite versatile and can be used at different depths to address a wide variety of concerns on the face.' Aside from the fact that it smooths dynamic smile lines and laugh lines, augments, and restores volume to areas of the face, Evolysse doesn't cause the lumps and bumps that can potentially form post-injection. 'One of the adverse effects of hyaluronic acid fillers is sometimes delayed onset of nodules, the little lumps, bumps, or granulomas around where the filler is placed,' explains Dr. Karen. By using Cold-X Technology and maintaining the natural form of hyaluronic acid by not having to crosslink it as much, 'they are finding both in the initial pivotal study, and then in practice, there is basically a nonexistent rate of nodules. That's not to say it can't happen, but in their initial study, no delayed onset nodules formed,' Dr. Karen adds. As of now, according to that same study, Evolysse is shown to last for one year. It's important to note that the length of the study lasted only for 12 months, and that it's been reported that fillers can remain detectable in the face years longer than initially thought, so it's reasonable to infer that Evolysse lasts just as long as other hyaluronic acid-based injectables on the market in the long term. Anyone experiencing volume loss, particularly around the lower face, and who wants a natural look is a great candidate. Dr. Karen says both Smooth and Form are great for a highly mobile area, such as the mouth (you're chewing, talking, smiling, etc), because of how natural and delicate the product is. 'If you put something that is too lumpy or clumpy in that area, it may not give you the best result,' she says. Dr. Karen adds that there's really no one who isn't a good candidate, unless someone has major volume loss where their end-game aesthetics goals are not realistic from the use of injectables. As a beauty editor and self-proclaimed aesthetics guinea pig, I wanted to try Evolysse to fill in some areas of slight volume loss around my mouth that were bugging me. I visited Dr. Karen's office for my Evolysse treatment. After having numbing cream applied to my areas of concern in my lower face and sitting with it for about 10 minutes, Dr. Karen assessed my face, choosing to use Evolysse Form on me. She injected a little bit of Evolysse Form between my upper lip and cheek, the nasolabial fold, and the melolabial fold, or what people call the marionette. She also placed a little in the pre-jowl sulcus, which is that slight divot that people get at the lateral aspect of their chin, along the jawline. Thanks to the numbing cream, the experience was only very mildly uncomfortable. The whole thing took less than thirty minutes, and I saw the results of the product immediately. Though very subtle, the skin around my lower face looked smoother and slightly plumper. The immediate results are what Dr. Yang loves about the injectable. 'What's unique about Evolysse is that you can treat to correction, meaning what you see after injection is about what you can expect in the long run. With Cold-X Technology, these fillers do not swell as much as other HAs on the market, which can be a good thing depending on your treatment goals." Depending on your location, provider, and number of syringes needed, the cost may vary, but the price of Evolysse is comparable to other brands of hyaluronic acid-injectables. You can expect to pay around $900 to $1,500 for a syringe, but even this range may vary. For reference, Dr. Karen does not usually inject more than a syringe or two at a time during an appointment. While I certainly love the results from my Evolysse appointment and find them to be super natural, it ultimately does not look like I've had filler, which is arguably the whole point. Provided you go to an experienced injector, you Evolysse can definitely refresh your face without making you look overfilled or puffy. I also loved that the effects were instant—so when I left my appointment, I immediately felt good about my results. All in all, Evolysse is another great option to choose from if you're interested in fillers. Taryn is a beauty writer and editor in digital media with more than 10 years of experience. She has covered the newest and most innovative skincare and beauty products, aesthetic treatments, and plastic surgery trends. Her stories touch on everything from the best products to treat hyperpigmentation to why fat grafting is the better alternative to filler. In addition to Cosmopolitan, she currently contributes to Allure, InStyle, PS (formerly POPSUGAR), Marie Claire, The Zoe Report, and Bustle. In addition to her writing, Taryn directs, produces, and writes short films that have appeared at numerous film festivals around the country. Whenever she has a free moment, you can find her hopping around New York City with her Maltese pup, Bryn, and probably daydreaming about being at the beach. Follow her on Instagram for the latest.
Globe and Mail
22-07-2025
- Business
- Globe and Mail
Evolus to Report Second Quarter Financial Results on August 5, 2025
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13754888. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Jeuveau ® and Nuceiva ®, are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc.
Globe and Mail
11-07-2025
- Business
- Globe and Mail
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of July 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as applicable, covering the grant, including requirements to remain continuously employed on each vesting date. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook.
Time Business News
13-06-2025
- Health
- Time Business News
Evolysse Smart Hydration Redefined with Advanced HA Fusion Technology
In the ever-evolving world of skincare, hydration remains a cornerstone of healthy, radiant skin. However, traditional moisturizers often fall short in delivering deep, long-lasting hydration. Enter Evolysse Smart Hydration, a revolutionary skincare innovation powered by Advanced HA Fusion Technology. With increasing environmental stressors, pollution, and lifestyle factors impacting skin health, What is Evolysse demand for intelligent hydration solutions has never been higher. Evolysse combines science and nature to create a breakthrough formula that hydrates and enhances the skin's natural barrier, ensuring lasting moisture retention and a youthful glow. Skin hydration is more than just applying water or a basic moisturizer. The skin's outermost layer, the stratum corneum, relies on a delicate balance of water and lipids to maintain elasticity, suppleness, and protection. When this balance is disrupted, skin becomes dry, flaky, and prone to premature aging. Hyaluronic Acid (HA) is a naturally occurring molecule in the skin known for its exceptional water-retention capabilities. A single gram of HA can hold up to 1,000 times its weight in water, making it a hydration powerhouse. However, not all HA is created equal. Traditional HA molecules vary in size, affecting their penetration and efficacy. Most skincare products use standard HA, which: Only provides surface-level hydration Evaporates quickly without locking in moisture Fails to address deeper skin layers This is where Evolysse's Advanced HA Fusion Technology comes into play. What is Evolysse proprietary Advanced HA Fusion Technology is a multi-dimensional approach to hydration, combining: Multi-Molecular Weight HA – A blend of high, medium, and low-weight HA molecules ensures hydration penetrates every layer of the skin. High-weight HA forms a protective moisture barrier on the surface. Medium-weight HA hydrates the mid-layers for plumpness. Low-weight HA penetrates deeply to stimulate collagen and long-term hydration. Smart Delivery System – Encapsulated HA ensures controlled release, providing 24-hour hydration without the need for reapplication. Bio-Fermented HA – Sustainably sourced and bio-fermented for higher purity and enhanced skin compatibility. Feature Traditional HA Products Evolysse Smart Hydration Hydration Depth Surface-level only Multi-layered (deep, mid, surface) Duration Short-term (few hours) Long-lasting (24-hour release) Technology Standard HA Advanced HA Fusion + Smart Delivery Skin Benefits Temporary plumping Enhanced barrier, collagen support This intelligent system ensures that skin remains hydrated, resilient, and youthful throughout the day. Unlike traditional moisturizers that simply coat the skin's surface, Evolysse provides deep, continuous hydration at the cellular level, helping to prevent transepidermal water loss (TEWL). Evolysse strengthens the skin's natural lipid barrier, offering protection against environmental stressors such as pollution and UV exposure. Well-hydrated skin appears plumper, reducing the visibility of fine lines. The low-weight HA in Evolysse also stimulates collagen production for long-term anti-aging benefits. With consistent use, skin becomes more elastic and resilient, combating sagging and dullness. Whether you have dry, oily, combination, or sensitive skin, Evolysse's pH-balanced, non-comedogenic formula ensures optimal hydration without irritation. Traditional skincare takes a passive approach—adding moisture only when dryness is noticeable. In contrast, smart hydration, like that in Evolysse, is proactive, responding to the skin's needs in real time for continuous, adaptive care. The future of skincare lies in personalized hydration. Imagine a system where: Smart sensors detect skin's hydration levels AI adjusts HA delivery based on environmental conditions Custom-blended serums are created for individual needs Evolysse is at the forefront of this movement, paving the way for next-gen skincare innovations. Formulated with bio-fermented HA and housed in eco-conscious packaging, Evolysse supports the global move toward green beauty—delivering high performance without compromising the planet. Start with a gentle cleanser to remove impurities. Dispense 2-3 drops onto fingertips. Gently press onto face and neck. Allow absorption before layering other products. For maximum benefits, follow with a moisturizer or sunscreen. Morning & Night for optimal hydration. Under Makeup for a smooth, plump base. Evolysse Smart Hydration isn't just another skincare product—it represents a new era in skin wellness. Powered by Advanced HA Fusion Technology, it offers smarter, deeper, and longer-lasting hydration than conventional approaches. TIME BUSINESS NEWS
Yahoo
13-05-2025
- Business
- Yahoo
Evolus, Inc. (EOLS): A Bull Case Theory
We came across a bullish thesis on Evolus, Inc. (EOLS) on Substack by Greg ┃The Elevator Pitch. In this article, we will summarize the bulls' thesis on EOLS. Evolus, Inc. (EOLS)'s share was trading at $11.76 as of May 7th. EOLS's forward P/E was 117.65 according to Yahoo Finance. ATeam/ Evolus has quickly positioned itself as a disruptive force in the global injectable aesthetics market, traditionally dominated by pharmaceutical giants like AbbVie and Galderma. The company's flagship product, Jeuveau, has gained significant traction, capturing 13% of the U.S. neuromodulator market within just five years. Jeuveau's success can be attributed to its innovative go-to-market strategy, which combines pharmaceutical credibility with direct-to-consumer (DTC) marketing techniques typically associated with the beauty industry. By offering Jeuveau at a price point approximately 20% below Botox, it has been able to resonate with a younger demographic, particularly those between the ages of 20 and 40. This pricing strategy, combined with a robust presence in over 16,000 medical practices—including a growing number of medical spas that lack strong brand loyalty—has made Jeuveau a popular alternative to Botox. This market acceptance has positioned Evolus favorably in the expanding U.S. injectables market, which is undergoing structural changes driven by greater societal acceptance, a wider demographic appeal, and an aging population with increasing disposable income. The broader U.S. injectables market is seeing strong growth, with the popularity of non-invasive cosmetic procedures accelerating. The U.S. is expected to follow more mature markets like Korea, where injectables are already deeply embedded in cosmetic routines. This trend represents a significant growth opportunity for Evolus, which is now at a crucial inflection point in its business development. The company plans to diversify beyond neuromodulators with the upcoming launch of Evolysse, a premium line of dermal fillers developed in partnership with Symatese, the same formulation partner behind Galderma's Restylane. Evolus is seeking FDA approval for several aesthetic indications, including lip and cheek enhancement. This expansion into dermal fillers is expected to contribute approximately $200 million to Evolus' revenue over time, further strengthening its position in the injectables space. Moreover, Evolus is adopting an innovative subscription-based model, 'Club Evolus,' which offers customers quarterly treatments for a monthly fee. This model is designed to drive customer loyalty and predictable revenue streams, providing a clear path to sustained growth. With these initiatives in play, Evolus is targeting annual revenue growth of 25-27%, with projections aiming for $700 million in revenue by 2028, up from an estimated $266 million in 2024. If the company achieves these goals, it expects to reach positive cash flow by 2026. However, despite its promising growth trajectory, Evolus remains a high-risk, high-reward investment. Several factors introduce uncertainty, including regulatory dependencies around product approvals and manufacturing partnerships. Additionally, since all Evolus procedures are out-of-pocket and not covered by insurance, the company's performance is sensitive to broader consumer spending trends. Economic downturns could impact discretionary spending on cosmetic procedures, presenting a potential headwind to growth. Still, if Evolus can continue executing its strategy effectively, maintain rational competition, and convert growth into sustainable profits, the company could deliver significant upside to investors. Furthermore, Evolus' ability to capture market share in the growing injectable aesthetics sector—through innovation, branding, and consumer loyalty—positions it as a compelling investment despite the inherent risks. Evolus stands out among its competitors, particularly Galderma, which, although boasting successful injectable brands like Dysport and Restylane, has a more diluted business model. Galderma also operates legacy divisions, including skincare products like Cetaphil, which is losing ground to competitors like L'Oréal's Cerave, and a dermatological drug pipeline that limits its growth potential. In contrast, Evolus offers a cleaner, more focused investment thesis, solely concentrating on injectable aesthetics. While it is still smaller and must prove long-term profitability, the simplicity of Evolus' business model and its focus on high-growth injectables makes it a more attractive pure-play investment in the sector. Valuing Evolus is complex due to the limited number of direct competitors, but looking at mature self-pay therapeutic companies like Align, Sonova, and Alcon—whose valuations range from 13-17x EV/EBITDA—can provide some context. If Evolus reaches $700 million in revenue by 2028 and delivers an 11% EBITDA margin, which is lower than its 20% long-term target but adjusted for stock-based compensation, the company would generate approximately $77 million in EBITDA. Using a 15x EV/EBITDA multiple, this could result in annualized returns of around 20%, contingent on continued growth. However, key risks remain. Evolus relies on licensing agreements for its neuromodulator Jeuveau from Daewoong and its fillers from Symatese, both of which come with volume requirements and finite durations. Any disruptions to these agreements could create a going concern issue for the company. Moreover, competition from South Korean entrants and a fragmented filler market pose additional risks. As competition intensifies, pricing pressures could erode margins, further complicating Evolus' growth strategy. Another risk comes from tariffs. New U.S. import duties on products from South Korea and France could impact Jeuveau and Evolysse fillers, though they may be exempt as pharmaceuticals. If tariffs do apply, Evolus may need to raise prices by 5-6% to offset the cost increases, which could be manageable given the strong margins and pricing power of its products. Competitors like AbbVie and Galderma may also face similar tariff-related challenges, potentially leveling the playing field. Despite these risks, Evolus benefits from a seasoned management team, including executives with deep experience from Allergan, such as CEO David Moatazedi and CMO Rui Avelar. This leadership, combined with a focused business model and significant upside potential, makes Evolus a standout investment in the injectable aesthetics space. While the company must prove its long-term profitability, its focused approach and market opportunities position it for potential substantial growth in a rapidly expanding industry. Evolus, Inc. (EOLS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held EOLS at the end of the fourth quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of EOLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than EOLS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
